logo

Ignyta Inc. (RXDX)



Trade RXDX now with
  Date
  Headline
12/29/2017 7:01:55 AM Ignyta Reports FDA Clearance Of IND For RXDX-106
12/22/2017 1:02:03 AM Roche To Buy Ignyta For US$27.00/shr; Total Transaction Value Of US$1.7 Bln
10/17/2017 10:58:10 PM Ignyta Announces Updated Results From Clinical Trials, Including STARTRK-2 Trial
10/17/2017 7:04:23 AM Ignyta Receives European Medicines Agency Prime Designation For Entrectinib In NTRK Fusion-Positive Solid Tumors
9/6/2017 8:18:49 AM Ignyta Provides Regulatory Update On Entrectinib ROS1 Lung Cancer Development Program
7/10/2017 7:03:32 AM Ignyta Says FDA Granted Orphan Drug Designation To Entrectinib
5/4/2017 7:22:05 AM Ignyta Prices Public Offering Of 12.5 Mln Shares At $6.15 Per Share
12/1/2016 4:23:38 AM Ignyta Announces Data From An Ongoing Phase 1/1b Study Of RXDX-105
9/19/2016 7:10:15 AM EORTC And Ignyta Expand Collaborative Agreement For Precision Medicine
8/31/2016 7:04:27 AM Ignyta Announces Approval Of IDE For Companion Diagnostic Assay To The STARTRK-2 Trial
4/29/2016 6:03:35 AM Ignyta Prices Public Offering Of 8.0 Mln Common Shares At $6.25 Per Share